Marina I. Miller, Ph.D., is an intellectual property (IP) partner in the firm’s Chemical Patent Prosecution group and has extensive experience in patent applications preparation and all aspects of U.S. and foreign patent prosecution in diversified technologies within the pharmaceutical, chemical, biotechnology, medical, physics and engineering disciplines including recombinant DNA technology, genetics, immunology, enzymology, medical diagnostics, microarrays and statistical data analysis, genomics and proteomics, bioinformatics, nanotechnology and plasmonics, phototherapy, polymer chemistry, imaging, medical devices, optical films and coatings, cosmetics, catalysts, ceramics, alloys, chemical engineering, and optical and electronic devices. Her legal experience covers all aspects of client counseling, patent portfolio development and management, prosecution, post grant proceedings, appeals, opinions of counsel, due diligence, and pre-litigation counseling. She works actively with international and domestic clients to develop and grow their patent portfolios.
Dr. Miller has experience litigating pharmaceutical patents including abbreviated new drug application (ANDA) litigations, advising pioneering and generic pharmaceutical companies on U.S. Food and Drug Administration issues, and providing counseling and due diligence investigatory guidance. She has also evaluated IP issues that arise in corporate mergers and acquisitions and provided advice on building IP portfolios.
Prior to joining Oblon, Dr. Miller served as a Patent Examiner in the field of bioinformatics with the United States Patent and Trademark Office (USPTO). She also was a law clerk and scientific advisor in the IP litigation department of a leading national law firm, with an emphasis on client counseling and litigation in matters involving pharmaceutical compounds, formulations, polymorphs, genetically engineered crops, and polymers.
Her industry and academic experience includes working as a research scientist at the Center for Advanced Research in Biotechnology in Maryland, where she conducted structural studies of antigen recognition by T-cell receptors (TCRs) and T-cell activation by various superantigens. She was also a post-doctoral fellow at the Cornell Medical College at New York, where she researched the role of myosin-binding proteins in skeletal muscle and the heart. Dr. Miller is the author of 32 scientific publications and is named as an inventor on issued patents and patent applications worldwide.
Before attending law school, Dr. Miller received a Ph.D. in molecular biology/biochemistry from the All Union Research Institute of Genetics and Selection of Industrial Microorganisms in Moscow, Russia. Her thesis research focused on the discovery of a new approach for optimizing foreign gene expression in bacteria and expression and purification of different types of interleukins and chemokines. Dr. Miller also has a master’s degree in physics from the Moscow Physics-Engineering Institute.
Dr. Miller is fluent in Russian.
- University of Maryland School of Law (J.D.)
- Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia) (Ph.D.)
- Molecular Biology/Biochemistry
- Moscow Physics-Engineering Institute (MPEI) (Moscow, Russia) (M.S., summa cum laude)
- Moscow Physics-Engineering Institute (MPEI) (Moscow, Russia) (B.S., summa cum laude)
- District of Columbia
- U.S. Court of Appeals for the Federal Circuit
- Registered to practice before the U.S. Patent and Trademark Office
- America Bar Association
- American Intellectual Property Law Association (AIPLA)
- District of Columbia Bar Association
- Maryland Bar Association
Selected as a "Top Attorney of North America" in the 2015-16 edition of The Who’s Who Directories.
Selected Peer-Reviewed Publications:
- Lebedeva (Miller), M.I., Tsyba, N.A., Rogozkina, E.V., Mashko, S.V. (1994). A new T7 RNA polymerase-driven expression system induced via thermoamplification of a recombinant plasmid carrying a T7 promoter-E. coli lac. 142 Gene 61-66.
- Lebedeva (Miller), M.I., Reinach, F.A., Fischman, D.T. (1994). Identification of the MyBP-C (C-protein) binding site in the myosin rod. 8(4) The FASEB Journal A104.
- Fields, B.A., Ober, B., Malchiodi, E.L., Lebedeva (Miller), M.I., Braden, B.C., Ysern Xavier, Kim Jin-Kyoo, Shao Xuguang, Ward, E.S., Mariuzza, R.A. (1995). Crystal structure of Va domain of a T cell antigen receptor. 270 Science 1821-1824.
- Lebedeva (Miller), M.I., Fields, B.A., Spits Hergen, Panchamoorthy Govindaswamy, Brenner, M.B., Mariuzza, R.A. (1996). Cloning, expression, and crystallization of the Vd domain of a human gd T-cell receptor. 5 Prot Sci. 2638-2642.
- Li Hongmin, Lebedeva (Miller), M.I., Ward, E.S., Mariuzza, R.A. (1997). Dual conformations of a T cell receptor Va homodimer: Implications for variability in VaVb domain association. 269 J. Mol. Biol. 385-394.
- Li Hongmin*, Lebedeva (Miller), M.I.*, Llera, A.S., Fields, B.A., Brenner, M.B., Mariuzza, R.A. (1998). Structure of the Vd domain of a human gd T cell antigen receptor. 391 Nature 502-506. (Li H. and Lebedeva (Miller) M.I. contributed equally to this work)*
- Leder Lukas, Llera, A.S., Lavoie, P.M., Lebedeva (Miller), M.I., Li Hongmin, Sekaly Rafick-Pierre, Bohach, G.A., Gahr, P.J., Schlievert, P.M., Karjalainen Klaus, Mariuzza, R.A. (1998). A mutational analysis of the binding of Staphylococcal enterotoxins B and C3 to the T cell receptor b chain and MHC Class II. 187 J. Exp. Med. 1-11.